In a recently published study in the Diseases of the Colon & Rectum, a cohort of researchers executed a prospective, single-arm study to assess the safety and efficacy of RD2-Ver.02, an autologous whole blood product - in a flowable form - for the treatment of anal fistulas.

With a 69% rate of complete healing within 6 months, this innovative approach to perianal fistular disease treatment proved to be both safe and viable, achieving an acceptable healing rate for both cryptoglandular and Crohn's fistula in ano.

Graphic showing the new procedure

Read the full publication >

Watch the animated procedure >

ESCP Affiliates